Rabies virus antigen-specific human monoclonal antibodies (MAbs) that recognized either viral glycoprotein, ribonucleoprotein, or matrix proteins were generated. Only glycoprotein-specific MAb neutralized a variety of rabies viruses and protected laboratory rodents against lethal rabies virus infection. The determinant recognized by this MAb does not appear to reside in previously defined antigenic sites of the viral glycoprotein.
Rabies remains a significant human disease throughout the developing world (2, 15) . The World Health Organization advocates prompt use of human anti-rabies virus immunoglobulin (HRIG) or equine anti-rabies virus immunoglobulin together with the administration of vaccine for postexposure treatment of rabies (11, 14, 19) . Although anti-rabies virus antibodies appear to be an essential component in rabies virus postexposure treatment, the precise mechanisms of protection are unclear. Antibodies directed against the rabies virus glycoprotein (G protein) neutralize extracellular rabies virus and mediate both the complement lysis of rabies virus-infected cells and antibody-dependent cellular cytotoxicity (5) . Antibodies recognizing the G or RNP protein play important roles in potentiating the antigen-induced proliferative response and production of gamma interferon (IFN-y) by rabies virus-specific T lymphocytes; IFN--y is also involved in the protection against lethal rabies virus infection (7) .
Allergic reactions are a risk connected with equine antirabies virus immunoglobulin use; thus, HRIG is recommended for human postexposure treatment. Due to the cost of HRIG and the high incidence of human rabies virus exposures, there is often insufficient HRIG available to initiate the recommended postexposure treatments. Limited access to HRIG may contribute to the increasing number of postexposure failures (1) . For these reasons, it is desirable to develop human monoclonal antibodies (MAbs) to replace HRIG in the rabies virus postexposure treatment.
We describe the characterization of RNP-specific and G protein-specific human MAbs which exhibit activity against a broad spectrum of lyssavirus strains and efficacy in postexposure treatment of rabies virus-infected animals.
Human MAbs were prepared from peripheral B lymphocytes from vaccinees immunized with the human diploid cell rabies vaccine by a somatic cell hybridization technique as described by Ueki et al. (1Sa). Reactivity of MAbs was determined by the indirect fluorescent-antibody staining technique in live or acetone-fixed rabies virus-infected cells, as described before (9) , as well as by enzyme-linked immunosorbent assay (ELISA) (4). The CVS-11, ERA, and PM strains of rabies virus as well as natural street rabies virus isolates and the rabies virus-related Duvenhage and Mokola viruses were propagated in BHK-21 cell culture monolayers, * Corresponding author.
as described before (16) . Rabies virus antigens were purified as described before (6, 13 tion-resistant escape variant was selected as described before (17) . The reactivity of this variant (CVS-11 RV 57) was determined against a panel of anti-G protein MAbs by a neutralization test (Fig. 1) blot analyses were performed as described previously (3, 8) . MAbs 56 and 105 reacted strongly to the denatured RNP protein (Fig. 2) ; MAbs 57 and 58 both recognize denatured G protein, suggesting that the epitopes recognized by these antibodies are probably continuous in nature. One MAb (MAb 52), which demonstrated RNP specificity in ELISA tests, reacted in Western blots with the N protein and weakly with the G protein. However, the activity is most likely unspecific, because MAb 52 did not recognize G protein in the ELISA.
Since MAb 57 was capable of neutralizing various rabies virus strains in vitro, we investigated whether treatment of mice or hamsters with this antibody could prevent a lethal rabies virus infection in pre-or postexposure situations. Six-week-old female ICR mice (Harlan Sprague-Dawley) in groups of 7 to 10 were inoculated intramuscularly (i.m.) into the right gastrocnemius muscle with 0.1 ml of one of five serial dilutions (100 to 0.16 IU) of either human MAb 57 or the virus-neutralizing mouse MAb 523-11. Twenty-four hours after MAb treatment, all mice were inoculated i.m. in the left gastrocnemius muscle with 10 50% mouse intracerebral lethal doses (MICLD50) of CVS-24 rabies virus. Animals were observed for 3 weeks, and deaths were reported daily. Pretreatment of mice with MAb 57 effectively prevented a lethal rabies virus infection ( 
